Status:
COMPLETED
Trial of Plasma Exchange for Acute Renal Failure at the Onset of Myeloma
Lead Sponsor:
London Health Sciences Centre
Collaborating Sponsors:
Canadian Institutes of Health Research (CIHR)
The Kidney Foundation of Canada
Conditions:
Multiple Myeloma
Acute Renal Failure
Eligibility:
All Genders
18-81 years
Phase:
NA
Brief Summary
Background:Plasma exchange has been suggested to be of theoretical benefit in the treatment of acute renal failure at the onset of multiple myeloma. Two small-randomized trials provide conflicting evi...
Detailed Description
Hypothesis: 5 to 7 plasma exchanges in addition to conventional therapy at onset of myeloma with acute renal failure, reduces the composite outcome of death, dialysis dependence or a GFR \< 30 ml/min/...
Eligibility Criteria
Inclusion
- New diagnosis of multiple myeloma and progressive acute kidney failure. The former is defined as a bone marrow aspirate with \> 10% plasma cells and a monoclonal light chain in the urine, plasma or renal tissue. The latter is defined as a serum Creatinine \> 200 umol/L with a rise \> 50 umol/L in the preceding 2 weeks despite correction of hypercalcemia , hypovolemia and metabolic acidosis as required in a patient with a normal size kidney on ultrasound.
Exclusion
- \<18 or \> 81 years of age
- Obstruction on renal ultrasound (examination required)
- Use of intravenous contrast or non-steroidal anti-inflammatory drugs during the previous 2 weeks
- Prior treatment for myeloma
- Pregnancy
- Inability to sign informed consent
Key Trial Info
Start Date :
September 1 1998
Trial Type :
INTERVENTIONAL
End Date :
April 1 2004
Estimated Enrollment :
92 Patients enrolled
Trial Details
Trial ID
NCT00120263
Start Date
September 1 1998
End Date
April 1 2004
Last Update
March 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dr W F Clark
London, Ontario, Canada, N6A 4G5